Genetic alterations to the DNA damage repair pathway, namely germline BRCA mutations, play a role in treatment planning for patients with early-stage breast cancer. Therefore, understanding key disease- and patient-specific factors that should prompt genetic testing is crucial for optimizing outcomes and personalizing treatment for your patients. In this engaging Clinical Case Challenge: test your ability to determine key patient- and disease-specific features that necessitate genetic testing in early-stage breast cancer determine situations where targeting known genetic alterations improves outcomes in early-stage breast cancer compete with other healthcare professionals for the top spot on the leaderboard receive immediate feedback via expert-led, microlearning videos outlining key clinical evidence.
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/optimizing-genetic-testing-treatment-selection-among-patients-high-risk-early
- Start Date: 2024-10-11 05:00:00
- End Date: 2024-10-11 05:00:00
- Credit Details: AAPA Category 1 Credit™️: 0.25 hours
AMA PRA Category 1 Credit™️: 0.25 hours
Nursing: 0.25 hours
Pharmacy: 0.25 hours - Commercial Support: Source: AstraZeneca (Any division) - Amount: 37375.0 - Is Kind Support: False Source: Merck (Any division) - Amount: 13875.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all